ATE346063T1 - Kristalline form von omeprazol - Google Patents

Kristalline form von omeprazol

Info

Publication number: ATE346063T1
Authority: AT; Austria
Prior art keywords: omeprazole; crystalline form; methoxy; disclosed; sulfiny
Prior art date: 2001-04-25

Application number

AT02764081T

Other languages

English (en)

Inventor

Milae N Hafner

Anton Eopar

Barbara Podobnik

Beleie A Cizerle

Alenka Kosak

Brina Ornik

Uros Urleb

Original Assignee

Lek Tovarna Farmacevtskih

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-25

Filing date

2002-04-24

Publication date

2006-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE346063(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-24 Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih

2006-12-15 Application granted granted Critical

2006-12-15 Publication of ATE346063T1 publication Critical patent/ATE346063T1/de

Links

SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title abstract 5
229960000381 omeprazole Drugs 0.000 title abstract 5
-1 4-methoxy-3,5-dimethyl-2-pyridinyl Chemical group 0.000 abstract 1
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT02764081T 2001-04-25 2002-04-24 Kristalline form von omeprazol ATE346063T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SI200100111A SI20875A (sl)	2001-04-25	2001-04-25	Kristalna oblika omeprazola

Publications (1)

Publication Number	Publication Date
ATE346063T1 true ATE346063T1 (de)	2006-12-15

Family

ID=20432882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02764081T ATE346063T1 (de)	2001-04-25	2002-04-24	Kristalline form von omeprazol

Country Status (26)

Country	Link
US (2)	US20040122056A1 (de)
EP (1)	EP1390360B1 (de)
JP (1)	JP4455815B2 (de)
KR (1)	KR20030094358A (de)
CN (1)	CN1531533B (de)
AT (1)	ATE346063T1 (de)
AU (1)	AU2002307892B2 (de)
BG (1)	BG108287A (de)
BR (1)	BR0209103A (de)
CA (1)	CA2445251C (de)
CZ (1)	CZ20032911A3 (de)
DE (1)	DE60216273T2 (de)
HR (1)	HRP20030853B1 (de)
HU (1)	HUP0303928A2 (de)
IL (1)	IL158561A0 (de)
MX (1)	MXPA03009789A (de)
NO (1)	NO20034715L (de)
NZ (1)	NZ528917A (de)
PL (1)	PL366471A1 (de)
RS (1)	RS50880B (de)
RU (1)	RU2286991C2 (de)
SI (2)	SI20875A (de)
SK (1)	SK13192003A3 (de)
UA (1)	UA77671C2 (de)
WO (1)	WO2002085889A1 (de)
ZA (1)	ZA200307988B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en)	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) *	2004-07-02	2007-06-01	Esteve Quimica, S.A.	Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1904064A4 (de) *	2005-07-07	2009-12-02	Reddys Lab Ltd Dr	Omeprazol form b
RU2435782C2 (ru) *	2006-02-22	2011-12-10	Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк.	Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
CA2665226C (en)	2006-10-05	2014-05-13	Santarus, Inc.	Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en)	2006-10-27	2008-05-01	The Curators Of The University Of Missouri	Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EA200900985A1 (ru)	2007-01-31	2009-12-30	Крка, Товарна Здравил, Д. Д., Ново Место	Способ получения оптически чистого омепразола
RU2339631C1 (ru) *	2007-04-12	2008-11-27	Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН)	Способ получения эзомепразола
WO2010134099A1 (en)	2009-05-21	2010-11-25	Cadila Healthcare Limited	One pot process for preparing omeprazole and related compounds
CN102786513A (zh) *	2011-05-18	2012-11-21	中国医学科学院药物研究所	奥美拉唑晶e型物质及制备方法与在药品和保健品中应用
CN102351846B (zh) *	2011-09-07	2012-08-22	周晓东	一种新的奥美拉唑钠化合物及其药物组合物
KR101459088B1 (ko) *	2012-08-02	2014-12-02	대화제약 주식회사	알-라베프라졸, 이의 금속염의 제조방법
IL312564A (en) *	2021-11-05	2024-07-01	Cinclus Pharma Holding Ab Publ	Polymorphs of the hydrochloride salt of linfarezan glurate
JP2025532389A (ja)	2022-10-04	2025-09-29	ザビリュク，アルセニー	大動脈弁の石灰化の抑制
CN119320381B (zh) *	2024-10-14	2025-12-12	山东益康药业股份有限公司	奥美拉唑与3,5-二硝基苯甲酸的共晶物及其用途
CN119320380B (zh) *	2024-10-14	2025-11-25	山东益康药业股份有限公司	奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
JP3282731B2 (ja) *	1990-06-15	2002-05-20	メルクエンドカムパニーインコーポレーテッド	結晶の構造および大きさを改良する結晶化方法
SE510666C2 (sv) *	1996-12-20	1999-06-14	Astra Ab	Nya Kristallmodifikationer
SI20019A (sl) *	1998-07-13	2000-02-29	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
US6166213A (en) *	1998-08-11	2000-12-26	Merck & Co., Inc.	Omeprazole process and compositions thereof
UA72748C2 (en) *	1998-11-10	2005-04-15	Astrazeneca Ab	A novel crystalline form of omeprazole
AUPQ841800A0 (en) *	2000-06-28	2000-07-20	Biomolecular Research Institute Limited	Truncated egf receptor
US6627646B2 (en) *	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs

2001
- 2001-04-25 SI SI200100111A patent/SI20875A/sl not_active IP Right Cessation
2002
- 2002-04-24 DE DE60216273T patent/DE60216273T2/de not_active Expired - Lifetime
- 2002-04-24 EP EP02764081A patent/EP1390360B1/de not_active Expired - Lifetime
- 2002-04-24 HU HU0303928A patent/HUP0303928A2/hu unknown
- 2002-04-24 MX MXPA03009789A patent/MXPA03009789A/es active IP Right Grant
- 2002-04-24 PL PL02366471A patent/PL366471A1/xx not_active Application Discontinuation
- 2002-04-24 CA CA2445251A patent/CA2445251C/en not_active Expired - Lifetime
- 2002-04-24 AU AU2002307892A patent/AU2002307892B2/en not_active Expired
- 2002-04-24 US US10/475,239 patent/US20040122056A1/en not_active Abandoned
- 2002-04-24 WO PCT/IB2002/001350 patent/WO2002085889A1/en not_active Ceased
- 2002-04-24 RS YUP-840/03A patent/RS50880B/sr unknown
- 2002-04-24 AT AT02764081T patent/ATE346063T1/de active
- 2002-04-24 HR HR20030853A patent/HRP20030853B1/xx not_active IP Right Cessation
- 2002-04-24 UA UA2003109492A patent/UA77671C2/uk unknown
- 2002-04-24 KR KR10-2003-7013767A patent/KR20030094358A/ko not_active Ceased
- 2002-04-24 CZ CZ20032911A patent/CZ20032911A3/cs unknown
- 2002-04-24 JP JP2002583416A patent/JP4455815B2/ja not_active Expired - Lifetime
- 2002-04-24 IL IL15856102A patent/IL158561A0/xx unknown
- 2002-04-24 SI SI200230491T patent/SI1390360T1/sl unknown
- 2002-04-24 CN CN028089553A patent/CN1531533B/zh not_active Expired - Lifetime
- 2002-04-24 SK SK1319-2003A patent/SK13192003A3/sk unknown
- 2002-04-24 RU RU2003133213/04A patent/RU2286991C2/ru active
- 2002-04-24 BR BR0209103-8A patent/BR0209103A/pt not_active Application Discontinuation
- 2002-04-24 NZ NZ528917A patent/NZ528917A/en unknown
2003
- 2003-10-14 ZA ZA200307988A patent/ZA200307988B/xx unknown
- 2003-10-21 NO NO20034715A patent/NO20034715L/no not_active Application Discontinuation
- 2003-10-24 BG BG108287A patent/BG108287A/bg unknown
2005
- 2005-10-12 US US11/248,461 patent/US7553856B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
KR20030094358A (ko)	2003-12-11
SK13192003A3 (sk)	2004-03-02
EP1390360B1 (de)	2006-11-22
CN1531533A (zh)	2004-09-22
SI20875A (sl)	2002-10-31
CN1531533B (zh)	2012-07-18
NO20034715L (no)	2003-12-10
CZ20032911A3 (en)	2004-06-16
HUP0303928A2 (hu)	2004-03-01
CA2445251C (en)	2011-01-04
YU84003A (sh)	2006-08-17
NZ528917A (en)	2006-02-24
RU2286991C2 (ru)	2006-11-10
PL366471A1 (en)	2005-02-07
SI1390360T1 (sl)	2007-04-30
US7553856B2 (en)	2009-06-30
JP2004526786A (ja)	2004-09-02
UA77671C2 (en)	2007-01-15
US20060079560A1 (en)	2006-04-13
NO20034715D0 (no)	2003-10-21
HRP20030853A2 (en)	2005-08-31
EP1390360A1 (de)	2004-02-25
RU2003133213A (ru)	2005-05-10
JP4455815B2 (ja)	2010-04-21
CA2445251A1 (en)	2002-10-31
AU2002307892B2 (en)	2008-04-17
DE60216273D1 (de)	2007-01-04
IL158561A0 (en)	2004-05-12
HRP20030853B1 (en)	2011-11-30
RS50880B (sr)	2010-08-31
BG108287A (bg)	2005-04-30
MXPA03009789A (es)	2005-03-07
DE60216273T2 (de)	2007-05-31
ZA200307988B (en)	2004-10-14
US20040122056A1 (en)	2004-06-24
BR0209103A (pt)	2004-07-13
WO2002085889A1 (en)	2002-10-31

Legal Events

Date

Code

Title

Description

2007-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1390360

Country of ref document: EP

Publication	Publication Date	Title
DE60216273D1 (de)	2007-01-04	Kristalline form von omeprazol
TR200101282T2 (tr)	2001-11-21	Omeprozolün yeni kristalli formu
AR010361A1 (es)	2000-06-07	"S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"
MY127871A (en)	2006-12-29	Omeprazole sodium salt
CA2357744A1 (en)	2000-08-03	Potassium salt of (s)-omeprazole
WO1998054171A8 (en)	1999-12-23	Novel form of s-omeprazole
MY111737A (en)	2000-12-30	Use of omeprazole as an antimicrobial agent.
JP2002535401A5 (de)	2007-01-25
AR013740A1 (es)	2001-01-10	Proceso para la preparacion de omeprazol, compuesto y formulacion farmaceutica del mismo
ATE363480T1 (de)	2007-06-15	Alkylammoniumsalze von omeprazol und esomeprazol
AU4671499A (en)	2000-02-01	Improved process of synthesis of 5-methoxy- 2-((4-methoxy- 3,5-dimethyl- 2-pyridyl)methyl)sulfinyl-1h-benzimidazole
SE0302382D0 (sv)	2003-09-04	New salts II
JP2007504223A5 (de)	2007-09-27
JP2007504222A5 (de)	2007-09-27
SE0302381D0 (sv)	2003-09-04	New salts I
MY118724A (en)	2005-01-31	New crystalline form of omeprazole
YU32301A (sh)	2005-07-19	Novi kristalni oblik omeprazola
JP2005523298A (ja)	2005-08-04	非心臓性胸痛の治療のためのプロトンポンプ阻害剤の使用